Aspirin
Stroke Disorder
Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
China National Center for Cardiovascular Diseases
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05963568CT.gov Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment II Study (SMAART II) | — | Not Yet Recruiting | — | — | — |
NCT07619885CT.gov The Pharmacokinetics and Pharmacodynamics Study of CG-0255 Besylate and Plavix® in Healthy Participants | — | Recruiting | — | — | — |
NCT07237308CT.gov BEACON-AA: Apixaban With or Without Clopidogrel in Stroke Patients With Atrial Fibrillation and Cerebral Atherosclerosis | — | Not Yet Recruiting | — | — | — |
NCT07095790CT.gov Tirofiban With Sequential Dual Antiplatelet Therapy in Mild Stroke | — | Recruiting | — | — | — |
NCT06486792CT.gov Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation | — | Recruiting | — | — | — |
NCT06587347CT.gov Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke | — | Not Yet Recruiting | — | — | — |
NCT06530537CT.gov Cilostazol vs. Aspirin in Acute Non-cardioembolic Stroke With Cerebral mIcrobleeds | — | Recruiting | — | — | — |
NCT05902000CT.gov Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion | — | Unknown | — | — | — |
NCT05476991CT.gov Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | — | Recruiting | — | — | — |
NCT05047172CT.gov Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis | — | Active Not Recruiting | — | — | — |
Show 40 more trialsShow fewer
NCT04733742CT.gov Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke | — | Completed | — | — | — |
NCT04516993CT.gov CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II | — | Completed | — | — | — |
NCT04948749CT.gov Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial | — | Recruiting | — | — | — |
NCT04491695CT.gov Tirofiban for the Prevention of Neurological Deterioration in Acute Ischemic Stroke | — | Unknown | — | — | — |
NCT03978988CT.gov Thrombectomy In TANdem Occlusion | — | Active Not Recruiting | — | — | — |
NCT04045665CT.gov Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | — | Recruiting | — | — | — |
NCT04097912CT.gov Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels | — | Completed | — | — | — |
NCT04078737CT.gov Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II | — | Completed | — | — | — |
NCT03635749CT.gov Intensive Medical Therapy for High-risk Intracranial or Extracranial Atherosclerosis | — | Unknown | — | — | — |
NCT03192215CT.gov AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke | — | Terminated | — | — | — |
NCT04962451CT.gov Comparison of the Efficacy of Ticagrelor Combined With ASA to ASA Alone in Patients With Stroke | — | Completed | — | — | — |
NCT02975076CT.gov Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study | — | Unknown | — | — | — |
NCT02921360CT.gov Early Administration of Aspirin in Patients With Acute Ischemic Stroke Treated With Systemic Thrombolysis | — | Unknown | — | — | — |
NCT02168829CT.gov Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial | — | Completed | — | — | — |
NCT02550717CT.gov Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN) | — | Completed | — | — | — |
NCT02506140CT.gov Platelet Reactivity in Acute Non-disabling Cerebrovascular Events | — | Completed | — | — | — |
NCT01938248CT.gov Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation | — | Completed | — | — | — |
NCT02398656CT.gov A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion | — | Completed | — | — | — |
NCT02313909CT.gov Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) | — | Terminated | — | — | — |
NCT02446730CT.gov Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome | — | Unknown | — | — | — |
NCT02878772CT.gov Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients | — | Completed | — | — | — |
NCT02247128CT.gov Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation | — | Completed | — | — | — |
NCT02221102CT.gov Edoxaban for TIA and Acute Minor Stroke | — | Unknown | — | — | — |
NCT01642134CT.gov Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI | — | Completed | — | — | — |
NCT01518231CT.gov Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke | — | Unknown | — | — | — |
NCT01141153CT.gov Anticoagulation in Stent Intervention | — | Unknown | — | — | — |
NCT01038583CT.gov Aspirin in Reducing Events in the Elderly | — | Unknown | — | — | — |
NCT00805311CT.gov Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis | — | Terminated | — | — | — |
NCT01661322CT.gov Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke | — | Terminated | — | — | — |
NCT00724724CT.gov The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial | — | Unknown | — | — | — |
NCT00847860CT.gov Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Matter Lesions | — | Completed | — | — | — |
NCT00562588CT.gov EARLY 3-months Aggrenox Treatment Started Within 24 Hrs of Ischemic Stroke Onset vs. After One Week 100 mg ASA | — | Completed | — | — | — |
NCT00363753CT.gov Pilot Study of Continuing Aspirin Versus Switching to Clopidogrel After Stroke or Transient Ischemic Attack | — | Withdrawn | — | — | — |
NCT00311402CT.gov JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme | — | Completed | — | — | — |
NCT00263393CT.gov Rural Andhra Pradesh Cardiovascular Prevention Study (RAPCAPS) | — | Completed | — | — | — |
NCT00238667CT.gov To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection | — | Completed | — | — | — |
NCT00153062CT.gov PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes | — | Completed | — | — | — |
NCT00276380CT.gov A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke | — | Completed | — | — | — |
NCT00027066CT.gov Warfarin Versus Aspirin Recurrent Stroke Study | — | Completed | — | — | — |
NCT00004727CT.gov Antiplatelet Therapy to Prevent Stroke in African Americans | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Aspirin (this asset) | China National Center for Cardiovascular Diseases | Approved | BB · 71 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Atorvastatin | Duan Chuanzhi | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Aspirin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myocardial Infarction | — | P4 | A · 83 |
| Coronary Artery Disorder | — | P4 | BBB · 79 |
| Cardiovascular Disorder | — | P4 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Aspirin in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/aspirin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →